170 related articles for article (PubMed ID: 22614936)
1. Counseling and directly observed medication for primary care buprenorphine maintenance: a pilot study.
Moore BA; Barry DT; Sullivan LE; Oʼconnor PG; Cutter CJ; Schottenfeld RS; Fiellin DA
J Addict Med; 2012 Sep; 6(3):205-11. PubMed ID: 22614936
[TBL] [Abstract][Full Text] [Related]
2. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.
Fiellin DA; Pantalon MV; Chawarski MC; Moore BA; Sullivan LE; O'Connor PG; Schottenfeld RS
N Engl J Med; 2006 Jul; 355(4):365-74. PubMed ID: 16870915
[TBL] [Abstract][Full Text] [Related]
3. Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial.
Schramm ZA; Leroux BG; Radick AC; Ventura AS; Klein JW; Samet JH; Saxon AJ; Kim TW; Tsui JI
Addict Sci Clin Pract; 2020 Jul; 15(1):30. PubMed ID: 32736660
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of the feasibility, acceptability, and preliminary efficacy of cognitive-behavioral therapy for opioid use disorder and chronic pain.
Barry DT; Beitel M; Cutter CJ; Fiellin DA; Kerns RD; Moore BA; Oberleitner L; Madden LM; Liong C; Ginn J; Schottenfeld RS
Drug Alcohol Depend; 2019 Jan; 194():460-467. PubMed ID: 30508769
[TBL] [Abstract][Full Text] [Related]
5. Cognitive Behavioral Therapy Improves Treatment Outcomes for Prescription Opioid Users in Primary Care Buprenorphine Treatment.
Moore BA; Fiellin DA; Cutter CJ; Buono FD; Barry DT; Fiellin LE; O'Connor PG; Schottenfeld RS
J Subst Abuse Treat; 2016 Dec; 71():54-57. PubMed ID: 27776678
[TBL] [Abstract][Full Text] [Related]
6. Comparison of buprenorphine treatment for opioid dependence in 3 settings.
Miotto K; Hillhouse M; Donovick R; Cunningham-Rathner J; Charuvastra C; Torrington M; Esagoff AE; Ling W
J Addict Med; 2012 Mar; 6(1):68-76. PubMed ID: 22105061
[TBL] [Abstract][Full Text] [Related]
7. Primary care patient characteristics associated with completion of 6-month buprenorphine treatment.
Neumann AM; Blondell RD; Azadfard M; Nathan G; Homish GG
Addict Behav; 2013 Nov; 38(11):2724-8. PubMed ID: 23934003
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.
Sigmon SC; Dunn KE; Saulsgiver K; Patrick ME; Badger GJ; Heil SH; Brooklyn JR; Higgins ST
JAMA Psychiatry; 2013 Dec; 70(12):1347-54. PubMed ID: 24153411
[TBL] [Abstract][Full Text] [Related]
9. Behavioral drug and HIV risk reduction counseling (BDRC) with abstinence-contingent take-home buprenorphine: a pilot randomized clinical trial.
Chawarski MC; Mazlan M; Schottenfeld RS
Drug Alcohol Depend; 2008 Apr; 94(1-3):281-4. PubMed ID: 18164145
[TBL] [Abstract][Full Text] [Related]
10. A trial of integrated buprenorphine/naloxone and HIV clinical care.
Sullivan LE; Barry D; Moore BA; Chawarski MC; Tetrault JM; Pantalon MV; O'Connor PG; Schottenfeld RS; Fiellin DA
Clin Infect Dis; 2006 Dec; 43 Suppl 4():S184-90. PubMed ID: 17109305
[TBL] [Abstract][Full Text] [Related]
11. Bridging waitlist delays with interim buprenorphine treatment: initial feasibility.
Sigmon SC; C Meyer A; Hruska B; Ochalek T; Rose G; Badger GJ; Brooklyn JR; Heil SH; Higgins ST; Moore BA; Schwartz RP
Addict Behav; 2015 Dec; 51():136-42. PubMed ID: 26256469
[TBL] [Abstract][Full Text] [Related]
12. Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients.
Tetrault JM; Moore BA; Barry DT; O'Connor PG; Schottenfeld R; Fiellin DA; Fiellin LE
J Subst Abuse Treat; 2012 Dec; 43(4):433-9. PubMed ID: 22938914
[TBL] [Abstract][Full Text] [Related]
13. Comparison of behavioral treatment conditions in buprenorphine maintenance.
Ling W; Hillhouse M; Ang A; Jenkins J; Fahey J
Addiction; 2013 Oct; 108(10):1788-98. PubMed ID: 23734858
[TBL] [Abstract][Full Text] [Related]
14. Thrice-weekly versus daily buprenorphine maintenance.
Schottenfeld RS; Pakes J; O'Connor P; Chawarski M; Oliveto A; Kosten TR
Biol Psychiatry; 2000 Jun; 47(12):1072-9. PubMed ID: 10862807
[TBL] [Abstract][Full Text] [Related]
15. Randomized pilot trial of Web-based cognitive-behavioral therapy adapted for use in office-based buprenorphine maintenance.
Shi JM; Henry SP; Dwy SL; Orazietti SA; Carroll KM
Subst Abus; 2019; 40(2):132-135. PubMed ID: 30714880
[No Abstract] [Full Text] [Related]
16. A pilot study about the feasibility and cost-effectiveness of electronic compliance monitoring in substitution treatment with buprenorphine-naloxone combination.
Tacke U; Uosukainen H; Kananen M; Kontra K; Pentikänen H
J Opioid Manag; 2009; 5(6):321-9. PubMed ID: 20073406
[TBL] [Abstract][Full Text] [Related]
17. Inpatient initiation of buprenorphine maintenance vs. detoxification: can retention of opioid-dependent patients in outpatient counseling be improved?
Caldiero RM; Parran TV; Adelman CL; Piche B
Am J Addict; 2006; 15(1):1-7. PubMed ID: 16449087
[TBL] [Abstract][Full Text] [Related]
18. Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial.
Gunderson EW; Wang XQ; Fiellin DA; Bryan B; Levin FR
Addict Behav; 2010 May; 35(5):537-40. PubMed ID: 20106601
[TBL] [Abstract][Full Text] [Related]
19. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index.
Strain EC; Stitzer ML; Liebson IA; Bigelow GE
J Clin Psychopharmacol; 1996 Feb; 16(1):58-67. PubMed ID: 8834420
[TBL] [Abstract][Full Text] [Related]
20. A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults.
Marsch LA; Moore SK; Borodovsky JT; Solhkhah R; Badger GJ; Semino S; Jarrett K; Condon KD; Rossettie K; Vincent P; Hajizadeh N; Ducat E
Addiction; 2016 Aug; 111(8):1406-15. PubMed ID: 26918564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
